Cormorant Global Healthcare Master Fund, LP sold $46.8M of MoonLake Immunotherapeutics (MLTX)

Executed Sep 29 2025, disclosed Oct 1 2025, 2 days later.

Value, as filed

$46.8M

6,494,151 sh across 4 lots

Executed

Sep 29 2025

the trade date, as filed

Disclosed

Oct 1 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

CL Cormorant Global Healthcare Master Fund, LP Other profile →

Cormorant Global Healthcare Master Fund, LP (Other) filed 1 Form 4 report as a reporting entity in the trailing twelve months (0 purchases, 1 sale), most often in Corbus Pharmaceuticals Holdings, Inc. (CRBP). The largest single filing was $46.8M of MLTX (6,494,151 sh across 4 lots, as filed), executed Sep 29 2025.

The name

MLTX

MoonLake Immunotherapeutics MLTX · Healthcare · 18 filings in 24 months ticker →

Healthcare · MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseas…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→